BioCentury
ARTICLE | Finance

Solasia goes to market

Solasia becomes Japan’s first public biotech in months and looks to China

March 25, 2017 12:43 AM UTC
is a transdermal antagonist marketed as granisetron patch in the U.S. and Europe to treat chemotherapy-induced nausea and vomiting (CINV).

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans to use the proceeds to prepare to launch its first products in China.

Solasia raised ¥3.6 billion ($32 million) through the sale of 19.4 million shares at ¥185 in an IPO on Tokyo Stock Exchange's Mothers on Friday for a postmoney valuation of ¥15.5 billion ($138.4 million)...

BCIQ Company Profiles

Solasia Pharma K.K.